Bethanechol for Eosinophilic Esophagitis

Stopped early · Phase 2

Conditions studied: Eosinophilic Esophagitis (EoE)

In brief

The primary goals of this study are to ease the symptoms of patients with Eosinophilic Esophagitis (EoE) and to test the effectiveness of the drug bethanechol in relieving those symptoms.

Key facts

Study ID

NCT02058537

Run by

University of Iowa

People needed

2

Starts

2014-02-01

Expected to finish

2014-07-01

Last updated by the study team

2016-04-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or Female
• Age 18-75
• Symptoms associated with EoE such as dysphagia, heartburn, vomiting, abdominal pain, food impaction
• Subject has signed informed consent for the administration of bethanechol that informs the patient of potential adverse events
• Clinically or pathologically proven EoE

You may not qualify if…

• Known allergy to bethanechol
• Asthma
• Pregnant or breast-feeding women
• Severe neurological problems
• Severe diabetes
• Achalasia
• Known allergy to lidocaine or other local anesthetic
• Hypothyroidism
• Peptic ulcer
• Pronounced bradycardia or hypotension
• Vasomotor instability
• Coronary artery disease
• Epilepsy
• Parkinsonism
• Weakened gastrointestinal or bladder wall
• Mechanical obstruction of the gastrointestinal tract or bladder neck
• Urinary bladder surgery in the 6 months prior to the study
• Gastrointestinal resection and anastomosis
• Spastic gastrointestinal disturbances
• Acute inflammatory lesions of the gastrointestinal tract
• Peritonitis
• Marked vagotonia

Where it is running

• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.